KNE Kane Biotech Inc.

STEM Animal Health Appoints New President and CEO

STEM Animal Health Appoints New President and CEO
EN
13/10/2020

Underlying

KNEKane Biotech Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kane Biotech Inc.

 PRESS RELEASE
Free
KNE Kane Biotech In...

Kane Biotech Announces Publication of revyve® Wound Gel Article in the...

Kane Biotech Announces Publication of revyve® Wound Gel Article in the International Wound Journal WINNIPEG, Manitoba, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE) (“Kane Biotech” or “Kane”) announces the publication of an article on its revyve® Antimicrobial wound gel in the International Wound Journal. The article “Wound Healing Property of a Novel Thermo-Reversible Wound Gel With Lasting Antimicrobial and Antibiofilm Activity” is first-authored by Dr. Jeyachchandran Visvalingam, Internal R&D Leader, and includes authors from the Miller School of Medicine, Dr. Philli...

February 20, 2026 1 EN
 PRESS RELEASE
Free
KNE Kane Biotech In...

Kane Biotech Expands Commercial Activities in the United States

Kane Biotech Expands Commercial Activities in the United States WINNIPEG, Manitoba, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or the “Company”) today announces that it has signed non-exclusive distribution/sales agreements for its revyve® Antimicrobial Wound Gel® product line with Patient Care Medical (Austin, TX) and Life Biologics (Lakewood, NJ). US FDA 510(k) cleared and Health Canada approved revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray These U.S. non-exclusive distribution and sales agreements expand our prese...

February 19, 2026 1 EN
 PRESS RELEASE
Free
KNE Kane Biotech In...

Kane Biotech Announces FDA 510(k) Clearance for revyve® Antimicrobial ...

Kane Biotech Announces FDA 510(k) Clearance for revyve® Antimicrobial Skin and Wound Cleanser Company expands ISO 13485/MDSAP Certification to support growing wound care portfolio WINNIPEG, Manitoba, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSXV:KNE) (“Kane Biotech”. “Kane” or the “Company”) today announces two regulatory milestones that strengthen the Company’s wound care platform and reinforce its commitment to high quality, evidence-based medical device development. Kane has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its revyve® Antimicrobial S...

February 17, 2026 1 EN
 PRESS RELEASE
Free
KNE Kane Biotech In...

Kane Biotech Restarts Commercial Activities and Strengthens North Amer...

Kane Biotech Restarts Commercial Activities and Strengthens North American Management Company enters 2026 with renewed business momentum and key commercial appointments in the U.S. and Canada WINNIPEG, Manitoba, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces the resumption of commercial activities in both the United States and Canada for its revyve® Antimicrobial Wound Gel product line, alongside the appointment of two seasoned industry leaders to drive business development across North America.                ...

February 12, 2026 1 EN
 PRESS RELEASE
Free
KNE Kane Biotech In...

Kane Biotech Announces Closing of Private Placement Offering with an I...

Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces that today it has completed its previously announced non-brokered private placement offering (the “Offering”) of common shares of the Company (“Shares”). At the closing of the Offering, Kane issued 14,000,000 Shares at a price of $0.05 per Share for gross proceeds of $700,000 t...

December 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch